Pdt Partners, LLC Fibrogen Inc Transaction History

Pdt Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $9 - $82	-4 Reduced -0.0%	97,273 $262,000
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $604,552 - $954,397	37,903 Added 63.84%	97,277 $1.82 Million
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $137,357 - $183,523	-10,351 Reduced 14.85%	59,374 $951,000
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $1.16 Million - $1.49 Million	-102,186 Reduced 59.44%	69,725 $907,000
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $87,403 - $142,663	11,008 Added 6.84%	171,911 $1.82 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.79 $1.14 Million - $1.59 Million	94,648 Added 142.85%	160,903 $1.93 Million
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $657,912 - $1.02 Million	66,255 New	66,255 $934,000
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $315,337 - $605,882	-16,981 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$31.0 - $55.72 $526,411 - $946,181	16,981 New	16,981 $589,000
Q2 2020 Aug 14, 2020	SELL	$32.57 - $42.83 $849,360 - $1.12 Million	-26,078 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$23.3 - $45.96 $607,617 - $1.2 Million	26,078 New	26,078 $906,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.